Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Targeted Safety Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad domain, discussions of bone health and osteoporosis management have historically emphasized the benefits of bisphosphonate therapies, including Fosamax, in reducing fracture risk. This established context provided a framework for patients and clinicians to weigh treatment options against potential adverse effects. As scientific inquiry deepened, attention gradually shifted from generalized health outcomes to more specific safety considerations. Among these, the potential association between Fosamax exposure and osteonecrosis of the jaw emerged as a focal point for investigation. This transition required moving beyond broad health education toward a more targeted examination of risk factors linked to pharmaceutical use.

Bridging to Occupational and Clinical Risk

The pivot from general health context to occupational exposure concern becomes particularly relevant when considering populations with sustained, high-level contact with bisphosphonates. While initial discussions centered on patient populations receiving therapeutic doses, subsequent scrutiny expanded to include individuals whose professional activities involve handling or manufacturing such compounds. This shift reframes the inquiry from a purely clinical perspective to one that encompasses workplace environments, where repeated exposure may present distinct risk profiles. The transition thus bridges established health literacy with emerging occupational health considerations, setting the stage for focused analysis without delving into mechanistic claims.

Mechanistic Pathways and Scientific Evidence

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling. A recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation and diagnosis of ONJ typically involve exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis relies on clinical examination and imaging, with exclusion of metastatic disease or other jaw pathologies. The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and mechanical properties of the jawbone that may predispose it to ONJ under bisphosphonate therapy. The mechanistic pathways linking Fosamax to ONJ involve its potent inhibition of osteoclast activity, which suppresses bone turnover. In the jaw, this can impair the normal healing response to microtrauma or dental procedures, leading to avascular necrosis. Bisphosphonates accumulate in bone matrix and are released over time, potentially causing prolonged suppression of remodeling. Studies using animal models have investigated the effects of bisphosphonate (alendronate) treatment on jawbone, including assessments of static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that bisphosphonate therapy alters the mechanical and material properties of jawbone, which may contribute to ONJ development.

Risk Factors and Clinical Considerations

Risk factors for ONJ in patients taking Fosamax include invasive dental procedures such as tooth extraction, dental implants, or boney surgery; diagnosis of cancer; concomitant therapies like chemotherapy, corticosteroids, or angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known risk, its incidence in clinical trials was low and not statistically different from placebo, which may affect the perception of risk.

Causation and Temporal Relationships

Causation-related considerations for affected patients require careful evaluation of individual risk factors and temporal relationships. The timeline between exposure and documented harm can vary widely, with onset ranging from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), supporting a causal link. However, ONJ can also occur spontaneously in patients not taking bisphosphonates, complicating attribution. For patients with osteoporosis, the benefits of Fosamax in reducing fracture risk must be weighed against the potential for ONJ, especially given that the optimal duration of use has not been determined and for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, scientific evidence supports a causal association between Fosamax use and osteonecrosis of the jaw, with mechanistic pathways involving suppressed bone turnover and altered jawbone properties. Risk is increased by dental procedures and longer exposure. Warnings in the prescribing information address this risk, but clinical trial data show low incidence. Affected patients should be evaluated for risk factors and temporal patterns to assess causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

Scientific evidence indicates that Fosamax (alendronate) can cause osteonecrosis of the jaw (ONJ) through inhibition of osteoclast activity, leading to suppressed bone turnover and impaired healing. Studies using animal models have shown altered mechanical and material properties of jawbone after alendronate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077/). Clinical data report ONJ in patients taking bisphosphonates, with onset ranging from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. The risk increases with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and what is the typical clinical presentation?

ONJ is diagnosed by clinical examination and imaging, showing exposed bone in the jaw persisting for more than eight weeks, often with pain, swelling, infection, or delayed healing after dental procedures. It can occur spontaneously but is commonly associated with tooth extraction or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.